Clinical trail phases

Clinical Trials

Our department is currently actively participating in the following clinical trials:

Neoadjuvant

• Alliance A011202
  • PI: Dr. Robert Gabordi
  • A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
• NSABP B-51/RTOG 1304
  • PI: Dr. Robert Gabordi
  • A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Adjuvant

• NRG-BR003
  • PI: Dr. Bruce Hough
  • A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High Risk Node-Negative Triple-Negative Invasive Breast Cancer

Non-Therapeutic

• Agendia- Impact
  • PI: Dr. Robert Gabordi
  • Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry (IMPACt)

Treatment Resistant Disease

• NCI-MATCH
  • PI: Dr. Bruce Hough
  • Molecular Analysis for Therapy Choice (MATCH)
•  Arbor-Pharmaceuticals- Vigilant
  • PI: Dr. Samy Elhammady
  • Protocol AR22.001- Vigilant Observation of Gliadel WAfer ImplaNT (Vigilant) Registry to Collect Information on the Safety and Efficacy of Gliadel^®